Especifique uma ação ou criptomoeda na barra de pesquisa para obter um resumo
Almirall S.A.
0O9BAlmirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain. Address: Ronda General Mitre, 151, Barcelona, Spain, 08022
Analytics
Preço Alvo de Wall Street
12.4 EURRácio P/E
–Rendimento de dividendos
1.64 %Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Figuras chave 0O9B
Análise de Dividendos 0O9B
Crescimento de dividendos em 5 anos
–Crescimento contínuo
1 anoTaxa de pagamento em média de 5 anos
112 %Histórico de Dividendos 0O9B
Avaliação de ações 0O9B
Relatório 0O9B
Acompanhe as principais métricas de cada ação em um só lugar, sem complicações
Inscreva-se no premiumResultados | 2019 | Dinâmica |